Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Pfizer
City of Hope Medical Center
Eli Lilly and Company
OncoNano Medicine, Inc.
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
Antengene Corporation
IGM Biosciences, Inc.
BPGbio
National Cancer Institute (NCI)
Synlogic
OHSU Knight Cancer Institute
TopAlliance Biosciences
Rutgers, The State University of New Jersey
Innovent Biologics (Suzhou) Co. Ltd.
Chinese PLA General Hospital
Symphogen A/S
Seagen Inc.
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Symphogen A/S
Celgene
Menarini Group
Symphogen A/S
Incyte Corporation
Eli Lilly and Company
Eli Lilly and Company
Chinese PLA General Hospital
Incyte Corporation
National Institutes of Health Clinical Center (CC)
OHSU Knight Cancer Institute
Verastem, Inc.
Cornerstone Pharmaceuticals
H. Lee Moffitt Cancer Center and Research Institute
Mirati Therapeutics Inc.
Merck KGaA, Darmstadt, Germany
University of Chicago
Altor BioScience
City of Hope Medical Center
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Case Comprehensive Cancer Center
Pediatric Brain Tumor Consortium
Synta Pharmaceuticals Corp.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Enzon Pharmaceuticals, Inc.